Business Context and Reporting Period
On June 24, 2026, Absci Corporation (ABSI), a Delaware corporation, filed a Form 8-K Current Report. The filing announces the entry into a material definitive agreement for an underwriting of common stock. The company is an emerging growth company focused on AI-designed therapeutics.
Key Financial Metrics
- Offering Size: 13,495,277 shares of common stock.
- Offering Price: $7.41 per share.
- Estimated Net Proceeds: Approximately $93.5 million (after underwriting discounts, commissions, and estimated expenses).
- Use of Proceeds: Funding the advancement of ABS-201 (an AI-designed anti-PRLR antibody for androgenetic alopecia and endometriosis), working capital, and general corporate purposes.
- Closing Date: Expected on June 25, 2026.
The filing text does not provide current revenue, profit, cash flow, margins, debt, or liquidity metrics as this is a transactional report rather than a periodic financial statement.
Material Changes
This filing represents a significant capital raise event. The company has entered into an underwriting agreement with Jefferies LLC, J.P. Morgan Securities LLC, TD Securities (USA) LLC, and Guggenheim Securities, LLC. This transaction will increase the company's share count and cash position upon closing.
Outlook, Risks, and Management Commentary
Management intends to utilize the net proceeds to advance the clinical development of ABS-201. The underwriting agreement includes customary representations, warranties, market standoff provisions, and indemnification obligations. The offering was made pursuant to a shelf registration statement (File No. 333-289541) declared effective on August 22, 2025.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received on June 25, 2026.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific lock-up periods and market standoff provisions.
- Confirm the dilution impact of the 13,495,277 new shares on existing shareholders.
- Monitor subsequent filings for updates on the clinical progress of ABS-201 funded by this capital.